#melanoma

Immunotherapy Combo Improves Melanoma That Has Spread to Brain

Are the costs of screenings and the potential harms of overdiagnosis justified by the number of lives that could be lost to melanoma?

Other research groups have also found intriguing connections between cancer that has spread to the brain and neurodegenerative disorders.

New studies shed light on rates of depression, anxiety and the risks of self-harm and suicide in people diagnosed with cancer.

Watch six videos from the in-person Melanoma Exchange Patient Forum, including voices from cancer survivors, advocates and educators.

Latinos are less likely than their white counterparts to have melanoma, but when diagnosed, their cancer is usually more advanced.

Bill Evans, a melanoma survivor, turns his love of cycling into a community building and fundraising effort.

“It truly is great news”: Findings show that patients with BRAF-mutant melanoma start treatment with combination immunotherapy. [VIDEOS]

Kimmtrak, the first approved T-cell receptor therapy, improved overall survival in a clinical trial.

Medications that block the PSGL-1 protein promote an anti-tumor immune response in people with melanoma.

The success of the mRNA COVID-19 vaccines could help accelerate clinical research on vaccines to treat cancer.

Low fiber consumption and use of probiotics were linked to poorer response to checkpoint inhibitors for melanoma patients.

A combination of two immunotherapy drugs showed efficacy in the treatment of advanced melanoma in a phase 3 clinical trial.

Immunotherapy was far more effective than targeted therapy in extending survival for people with certain kinds of advanced melanoma.

Fiber intake of 20 grams was linked to longer survival for advanced melanoma patients—but use of probiotics was linked to worse outcomes.

Severe short-term caloric restriction is safe for cancer patients and is associated with activation of immune responses.

Images used to train artificial intelligence to diagnose skin cancer rarely include non-white people.